PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Bio-Gene Technology Limited (BGT.AX)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

AU000000BGT8

Sector

Healthcare

Highlights

Market Cap

A$7.45M

EPS (TTM)

-A$0.01

Total Revenue (TTM)

-A$435.00

Gross Profit (TTM)

-A$129.96K

EBITDA (TTM)

-A$924.00K

Year Range

A$0.03 - A$0.09

Target Price

A$0.37

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of A$10,000 in Bio-Gene Technology Limited, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-40.00%-30.00%-20.00%-10.00%0.00%10.00%20.00%SeptemberOctoberNovemberDecember2025February
-24.49%
15.76%
BGT.AX (Bio-Gene Technology Limited)
Benchmark (^GSPC)

Returns By Period

Bio-Gene Technology Limited had a return of -13.95% year-to-date (YTD) and -24.49% in the last 12 months.


BGT.AX

YTD

-13.95%

1M

2.78%

6M

-24.49%

1Y

-24.49%

5Y*

-27.83%

10Y*

N/A

^GSPC (Benchmark)

YTD

4.22%

1M

2.22%

6M

9.51%

1Y

22.46%

5Y*

12.74%

10Y*

11.29%

*Annualized

Monthly Returns

The table below presents the monthly returns of BGT.AX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202513.95%-13.95%
2024-6.67%-25.00%71.43%-9.72%-3.08%-22.22%8.16%-16.98%6.82%12.77%-16.98%-2.27%-28.33%
2023-0.00%-6.00%-14.89%31.25%-13.33%-14.29%8.97%5.88%-20.00%-9.72%-10.77%3.45%-40.00%
202212.20%26.09%5.17%-18.03%-40.00%-13.33%7.69%-21.43%-4.55%19.05%-8.00%-13.04%-51.22%
2021-3.57%7.41%-6.90%22.22%3.03%0.00%-5.88%-6.25%-10.00%40.74%5.26%2.50%46.43%
2020-10.00%-8.33%-15.15%32.14%-13.51%-18.75%3.85%-0.00%33.33%-19.44%-10.34%7.69%-30.00%
201920.00%-16.67%-1.00%-6.06%18.28%-18.18%55.56%17.86%3.03%-17.65%3.57%37.93%100.00%
2018-0.00%-2.56%-28.95%-0.00%18.52%3.13%-21.21%7.69%-7.14%7.69%10.71%-35.48%-48.72%
201710.00%-11.36%-2.50%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of BGT.AX is 35, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of BGT.AX is 3535
Overall Rank
The Sharpe Ratio Rank of BGT.AX is 3333
Sharpe Ratio Rank
The Sortino Ratio Rank of BGT.AX is 4141
Sortino Ratio Rank
The Omega Ratio Rank of BGT.AX is 4141
Omega Ratio Rank
The Calmar Ratio Rank of BGT.AX is 2929
Calmar Ratio Rank
The Martin Ratio Rank of BGT.AX is 3232
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Bio-Gene Technology Limited (BGT.AX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
The chart of Sharpe ratio for BGT.AX, currently valued at -0.23, compared to the broader market-2.000.002.004.00-0.231.77
The chart of Sortino ratio for BGT.AX, currently valued at 0.36, compared to the broader market-6.00-4.00-2.000.002.004.006.000.362.39
The chart of Omega ratio for BGT.AX, currently valued at 1.05, compared to the broader market0.501.001.502.001.051.32
The chart of Calmar ratio for BGT.AX, currently valued at -0.27, compared to the broader market0.002.004.006.00-0.272.66
The chart of Martin ratio for BGT.AX, currently valued at -0.60, compared to the broader market0.0010.0020.0030.00-0.6010.85
BGT.AX
^GSPC

The current Bio-Gene Technology Limited Sharpe ratio is -0.23. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Bio-Gene Technology Limited with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00SeptemberOctoberNovemberDecember2025February
-0.23
2.06
BGT.AX (Bio-Gene Technology Limited)
Benchmark (^GSPC)

Dividends

Dividend History


Bio-Gene Technology Limited doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-89.12%
-1.32%
BGT.AX (Bio-Gene Technology Limited)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Bio-Gene Technology Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Bio-Gene Technology Limited was 91.76%, occurring on Jan 24, 2025. The portfolio has not yet recovered.

The current Bio-Gene Technology Limited drawdown is 89.12%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-91.76%Mar 2, 2022734Jan 24, 2025
-67.84%Dec 5, 2017389Jun 24, 2019607Nov 9, 2021996
-33.33%Nov 10, 202129Dec 20, 202143Feb 23, 202272
-5.56%Feb 25, 20221Feb 25, 20221Feb 28, 20222

Volatility

Volatility Chart

The current Bio-Gene Technology Limited volatility is 59.36%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%50.00%60.00%SeptemberOctoberNovemberDecember2025February
59.36%
3.33%
BGT.AX (Bio-Gene Technology Limited)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Bio-Gene Technology Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Bio-Gene Technology Limited.


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab